Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 587457

Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes


Turk, Zdenka; Ljubić, Spomenka; Boras, Jozo
Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes // Diabetes
Philadelphia (PA), Sjedinjene Američke Države, 2012. str. A126-A126 (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 587457 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes

Autori
Turk, Zdenka ; Ljubić, Spomenka ; Boras, Jozo

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Diabetes / - , 2012, A126-A126

Skup
72nd Annual meeting of the American Diabetes Association (ADA)

Mjesto i datum
Philadelphia (PA), Sjedinjene Američke Države, 08.06.2012. - 12.06.2012

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Advanced glycation pathway; Type 2 diabetes; Hyperlipemia; Macrovascular disease; Endogenous secretory receptor for AGE; AGE-to-esRAGE ratio

Sažetak
Objective Endogenous secretory receptor for advanced glycation endproducts (esRAGE) an isoform of soluble RAGE, acts as decoy for AGEs. We hypothesized ratio of AGE-to-esRAGE could be link to atherosclerosis in diabetes. To examine this issue, we compared serum levels of esRAGE and methylglyoxal-adduct as well as the AGE-to-esRAGE ratio between type 2 diabetic patients with and without established macrovascular disease. Patients and Methods Methylglyoxal-adducts, AGEs and esRAGE were measured in type 2 diabetes (n=130) and healthy controls (n=30). A history of macrovascular events (cardiovascular disease, cerebral vasculopathy or peripheral vascular disease) was recorded in 50 subjects. Results esRAGE levels were lower in type 2 diabetic patients compared with control subjects (0.330±0.197 vs. 0.458±0.074 ng/ml, p=0.003). In diabetic population es RAGE correlated positively with MG-adducts, HbA1c, BMI, and triglyceride, and inversely with CRP, LDL and homocystein. Multiple stepwise regression analysis was performed to determine which parameters best predicted the esRAGE level. Finally, urinary MG-adduct excretion (p<0.001), AGEs (p<0.001), and AGE/esRAGE (p<0.001, inversely) remained to be independently associated circulatory esRAGE. Multiple stepwise regression model was used to evaluate the relationship between macrovascular disease as a dependent variable, and metabolic and AGE- parameters as independent variables. Analysis pointed to LDL (β=0.40 P=0.0001), HbA1c (β=0.37 P=0.0007), AGE/esRAGE (β=0.31 P=0.007) and homocysteine (β=0.25 P=0.013) as significant independent contributors to diabetic macrovascular disease. Conclusion A decreased level of esRAGE may therefore be a biomarker of atherosclerosis acting as either a decoy receptor or another mechanism.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
045-0000000-0165 - GLIKOTOKSINI U ŠEĆERNOJ BOLESTI I KRONIČNIM KOMPLIKACIJAMA (Turk, Zdenka, MZOS ) ( CroRIS)

Ustanove:
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac

Profili:

Avatar Url Jozo Boras (autor)

Avatar Url Zdenka Turk (autor)

Avatar Url Spomenka Ljubić (autor)


Citiraj ovu publikaciju:

Turk, Zdenka; Ljubić, Spomenka; Boras, Jozo
Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes // Diabetes
Philadelphia (PA), Sjedinjene Američke Države, 2012. str. A126-A126 (poster, međunarodna recenzija, sažetak, znanstveni)
Turk, Z., Ljubić, S. & Boras, J. (2012) Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes. U: Diabetes.
@article{article, author = {Turk, Zdenka and Ljubi\'{c}, Spomenka and Boras, Jozo}, year = {2012}, pages = {A126-A126}, keywords = {Advanced glycation pathway, Type 2 diabetes, Hyperlipemia, Macrovascular disease, Endogenous secretory receptor for AGE, AGE-to-esRAGE ratio}, title = {Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes}, keyword = {Advanced glycation pathway, Type 2 diabetes, Hyperlipemia, Macrovascular disease, Endogenous secretory receptor for AGE, AGE-to-esRAGE ratio}, publisherplace = {Philadelphia (PA), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }
@article{article, author = {Turk, Zdenka and Ljubi\'{c}, Spomenka and Boras, Jozo}, year = {2012}, pages = {A126-A126}, keywords = {Advanced glycation pathway, Type 2 diabetes, Hyperlipemia, Macrovascular disease, Endogenous secretory receptor for AGE, AGE-to-esRAGE ratio}, title = {Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes}, keyword = {Advanced glycation pathway, Type 2 diabetes, Hyperlipemia, Macrovascular disease, Endogenous secretory receptor for AGE, AGE-to-esRAGE ratio}, publisherplace = {Philadelphia (PA), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font